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OBJECTIVES: Uracil-tegafur (UFT), an oral anticancer agent, is
widely used to treat various types of cancer in many countries,
including Japan. The Japan Lung Cancer Research Group
(JLCRG) demonstrated that postoperative adjuvant chemother-
apy with UFT signiﬁcantly improves overall survival in patients
with stage I non-small-cell lung cancer, as compared with no
treatment after surgery (p = 0.04). Based on the results of the
JLCRG trial, we assessed the cost-effectiveness of UFT compared
to no treatment from a Japanese payer’s perspective.
METHODS: Data on individual patients of demographic char-
acteristics, clinical outcomes (survival) and medical resource use
including drug administration, consultations, treatment for
adverse events, post-relapse treatment were obtained from the
data base of the JLCRG trial. Medical costs were calculated
based on the Japanese national tariff. The incremental cost-
effectiveness ratio (ICER) of UFT in cost per life year gained over
a lifetime was estimated. Future costs and outcomes were dis-
counted at an annual rate of 3%. Sensitivity analyses were per-
formed on key parameters. RESULTS: A total of 979 patients
were included in the analysis. There were no signiﬁcant differ-
ences between the two groups in baseline characteristics. Total
medical costs from after surgery until death were $12,515 per
patient in the UFT group and $8522 per patient in the no treat-
ment group. The acquisition costs of UFT were $5464 per
patient. However, the costs of post-relapse treatment and
medical care up to the time of death were $937 and $686 lower
in the UFT group than in the no treatment group, respectively.
As compared with the no treatment group, the UFT group pro-
longed life by 0.74 years over a lifetime and ICER was $5367
per life year gained. This ﬁnding was not sensitive to plausible
variations in key parameters. CONCLUSIONS: Postoperative
adjuvant chemotherapy with UFT is cost-effective in patients
with non–small-cell lung cancer.
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ECONOMIC EVALUATION OF ANTIEMETIC REGIMENS FOR
PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA 
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OBJECTIVE: To evaluate the cost-effectiveness of antiemetic
regimens for prevention of chemotherapy-induced nausea and
vomiting. METHODS: A ﬁve-day decision model using efﬁcacy,
resource use and cost data from published sources, and expert
opinion was developed to determine the cost-effectiveness of four
antiemetic regimens: Regimen A) Aprepitant + Ondansetron +
Dexamethasone on day 1 and Aprepitant + Dexamethasone on
days 2 and 3 and only Dexamethasone on day 4; B) Ondansetron
+ Dexamethasone on day 1 and Dexamethasone on days 2–4;
C) Ondansetron + Dexamethasone on days 1–4; and D)
Ondansetron + Dexamethasone on day 1 and Dexamethasone +
Metoclopramide for days 2–4. A hypothetical cohort of 10,000
cancer patients scheduled to receive their ﬁrst cycle of single day,
outpatient, cisplatin-based highly emetogenic chemotherapy was
evaluated using Monte Carlo simulation. The primary outcome
measure was the cost per completely controlled patient (i.e., no
emesis and no use of rescue medications in both acute and
delayed phases). RESULTS: For regimens A, B, C, and D, the
expected costs from payer perspective were $593.45, $300.53,
$187.18, and $389.97, respectively. The expected costs from
societal perspective were $658.97, $431.56, $295.89 and
$494.84, respectively. Regimen A (67.6%) had highest expected
effectiveness followed by regimens C (55.5%), D (53.9%) and B
(47.8%). Regimens B and D were dominated by regimen C under
both perspectives. The incremental cost-effectiveness ratio
(ICER) per completely controlled patient for regimen A com-
pared to C was $3363.18 and $2881.61 from payer and societal
perspectives, respectively. The results were sensitive to the vari-
ations in the probability of no acute emesis and probability of
no delayed emesis given no acute emesis. CONLCUSIONS: This
study is among the ﬁrst to determine the cost-effectiveness of the
aprepitant-containing regimen compared to other combination
antiemetic regimens. The acceptability of regimen A as cost-
effective will depend on the acceptable threshold of ICER 




COMBINATION IN THE TREATMENT OF ADVANCED BREAST
CANCER AFTER FAILURE OF ANTHRACYCLINE THERAPY
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OBJECTIVE: To determine the cost-effectiveness of gemcitabine
plus paclitaxel (GT) therapy for patients with advanced breast
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